ApoB and Lp(a) target levels

For Indian adults, lower ApoB is better. Practical targets are <80 mg/dL if you have diabetes, hypertension, or a strong family history; <70 mg/dL if you have documented plaque or a coronary artery calcium (CAC) score >100 or are otherwise very high risk; consider <55 mg/dL in known atherosclerotic cardiovascular disease (ASCVD) or very high CAC. For lower‑risk adults, a starting goal of ≤90 mg/dL is reasonable. Lp(a) should be viewed as a risk amplifier. Levels ≥50 mg/dL (≈125 nmol/L) raise lifetime ASCVD risk; levels ≥180 mg/dL (≈430 nmol/L) are very high. Because there is no reliable way to lower Lp(a) directly, use an elevated value to set stricter LDL/ApoB goals and to intensify overall risk management. If Lp(a) is high, aim for LDL <70 mg/dL (or <55 mg/dL in very high risk), keep blood pressure <130/80 mmHg, manage diabetes per guideline A1c targets, avoid tobacco, and consider earlier or more intensive therapy with statin + ezetimibe or a PCSK9 inhibitor. A CAC scan can be useful to refine risk when uncertainty remains. Steps to lower ApoB: 1. Medications – statins are first‑line; add ezetimibe if needed; PCSK9 inhibitors (e.g., evolocumab, alirocumab) or REpatha for persistent high risk; bempedoic acid for statin‑intolerant patients. Niacin is not recommended for outcomes. 2. Diet – adopt an Indian‑adapted Mediterranean pattern: abundant vegetables, pulses (chana, rajma), soy/tofu, nuts; use primarily unsaturated oils such as canola, rice‑bran, sunflower, groundnut, and extra‑virgin olive oil for low‑heat cooking or salads; limit ghee, butter, red and processed meats; keep saturated fat <7‑10 % of calories. 3. Weight and activity – aim for a waist‑to‑height ratio ≤0.5 (men ≤90 cm waist, women ≤80 cm); exercise 150‑300 min/week, including 2‑3 days of resistance training and occasional vigorous intervals if tolerated. 4. Fiber and plant sterols – consume 25‑30 g of fiber daily from oats, barley, psyllium/ispaghol, etc.; consider plant‑sterol‑fortified foods, which can lower LDL/ApoB by ~5‑10 %. 5. Monitoring – recheck lipids and ApoB 6‑12 weeks after any therapeutic change, then every 6‑12 months; check Lp(a) at least once in a lifetime.